Advertisement

Document › Details
Argen-X N.V. (Argenx). (11/7/18). "Press Release: Argenx to Present at Upcoming Investor Conferences". Breda & Ghent.
![]() |
Region | London, Greater London |
Country | United Kingdom (GB) | |
![]() |
Organisation | Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX) |
Today | Argenx SE (Euronext + Nasdaq: ARGX) | |
Group | Argenx (Argen-X) (Group) | |
Organisation 2 | Credit Suisse (Group) | |
Today | Credit Suisse Group AG | |
![]() |
Product | Piper Jaffray Annual Healthcare Conference 2018 New York |
Product 2 | Jefferies 2018 London Healthcare Conference | |
![]() |
Index term | Argenx–Evercore: investor conference, 201811 supply service Argenx presents at Evercore ISI HealthCONx Conference 2018 |
Index term 2 | Argenx–Credit Suisse: investor conference, 201811 supply service Argenx presents at Credit Suisse Annual Healthcare Conference 2018 | |
![]() |
Person | Comijn, Joke (Argen-X 201704 Corp Communications Manager) |
Person 2 | DelGiacco, Beth (Argenx 201806– VP Investor Relations before Stern IR) | |
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that management will present at several upcoming investor conferences in November:
> Credit Suisse 27th Annual Healthcare Conference. Company presentation on Wednesday, November 14, 2018 at 1:40 p.m. MT in Scottsdale.
> Jefferies 2018 London Healthcare Conference. Company presentation on Thursday, November 15, 2018 at 3:20 p.m. UTC in London.
> Evercore ISI HealthCONx Conference. Company presentation on Tuesday, November 27, 2018 at 7:35 a.m. ET in Boston.
> Piper Jaffray 30th Annual Healthcare Conference. Company presentation on Wednesday, November 28, 2018 at 2:00 p.m. ET in New York City.
Live webcasts of each conference presentation will be available on the Company’s website at www.argenx.com. Replays of the webcasts will be available for 90 days following each presentation.
About argenx
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and the three antibody engineering technologies are designed to enable the expansion of the therapeutic index of the company’s product candidates.
www.argenx.com
For further information, please contact:
Joke Comijn, Director Corporate Communications & Investor Relations (EU)
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com
Beth DelGiacco, VP Investor Relations (US)
+1 518 424 4980
bdelgiacco@argenx.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” or “should” and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenx’s expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx’s reliance on collaborations with third parties; estimating the commercial potential of argenx’s product candidates; argenx’s ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx’s limited operating history; and argenx’s ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
Record changed: 2018-11-16 |
Advertisement

More documents for Argenx (Argen-X) (Group)
- [1] Argen-X N.V. (Argenx). (2/2/21). "Press Release: Argenx Raises $1.0 Billion in Gross Proceeds in a Global Offering". Breda....
- [2] Argenx SE. (1/6/21). "Press Release: Argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China". Breda, Shanghai & San Francisco, CA....
- [3] Argenx SE. (1/4/21). "Press Release: Argenx to Present at 39th Annual J.P. Morgan Healthcare Conference". Breda & Ghent....
- [4] Argenx SE. (10/6/20). "Press Release: Argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships". Breda & Ghent....
- [5] Argenx SE. (5/29/20). "Press Release: Argenx Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs". Breda & Ghent....
- [6] Argenx SE. (5/28/20). "Press Release: Argenx Raises $750 Million in Gross Proceeds in a Global Offering". Breda & Ghent....
- [7] Argenx SE. (5/26/20). "Press Release: Argenx Announces Launch of Proposed Global Offering". Breda & Ghent....
- [8] Argenx SE. (5/26/20). "Press Release: Argenx Announces Positive Topline Phase 3 ADAPT Trial Results". Breda & Ghent....
- [9] Oxford Nanopore Technologies Ltd.. (5/26/20). "Press Release: Oxford Nanopore Announces £48.4M ($59.2M) in New Capital to Support Ongoing Innovation and the Rapid Worldwide Growth of Nanopore Sequencing". Oxford....
- [10] Argenx SE. (11/8/19). "Press Release: Argenx Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs". Breda & Ghent....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top